1. Approval of Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31st March, 2026. 2. Recommendation of Final Dividend of Rs. 4.50/- per ....
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jeena Sikho Lifecare Ltd reported strong audited standalone results for FY ended March 2026. Revenue from operations grew 71% to Rs. 80,134.64 lakhs from Rs. 46,907.19 lakhs in the previous year. Profit after tax surged 178% to Rs. 22,217.57 lakhs from Rs. 7,994.33 lakhs, while EPS improved to Rs. 17.87 from Rs. 6.43. EBITDA margin expanded significantly from 31.3% to 44.7%, indicating improved operational efficiency. The company operates in two segments: Ayurvedic products/medicines and Ayurvedic healthcare services, with both showing robust growth. The Board recommended a final dividend of Rs. 4.50 per share (face value Rs. 2), subject to shareholder approval. Statutory auditors Walker Chandiok & Co LLP issued unmodified opinions on both standalone and consolidated financial statements.
The company demonstrated exceptional growth with over 70% revenue increase and nearly 178% PAT growth, indicating strong business momentum. The 13.4 percentage point improvement in EBITDA margin reflects successful cost management and operational scalability. The dividend recommendation signals management confidence and provides shareholder returns. Clean audit opinions with no qualifications support financial reporting reliability.